Quantifying aminoglycoside resistance in extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales clinical isolates: a retrospective cohort study

AIMS: Aminoglycoside resistance is frequently detected in extended-spectrum-beta-lactamase (ESBL)-producing Enterobacterales (ESBL-PE), questioning the appropriateness of aminoglycosides as empiric therapy in patients with suspected ESBL-PE infections. Therefore, we aimed to evaluate the frequency...

Full description

Saved in:
Bibliographic Details
Main Authors: Isabelle Vock, Lisandra Aguilar-Bultet, Nina Khanna, Adrian Egli, Elisabeth Wehrle-Wieland, Pranita D. Tamma, Sarah Tschudin Sutter
Format: Article
Language:English
Published: SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 2024-10-01
Series:Swiss Medical Weekly
Online Access:https://smw.ch/index.php/smw/article/view/3904
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850180492889948160
author Isabelle Vock
Lisandra Aguilar-Bultet
Nina Khanna
Adrian Egli
Elisabeth Wehrle-Wieland
Pranita D. Tamma
Sarah Tschudin Sutter
author_facet Isabelle Vock
Lisandra Aguilar-Bultet
Nina Khanna
Adrian Egli
Elisabeth Wehrle-Wieland
Pranita D. Tamma
Sarah Tschudin Sutter
author_sort Isabelle Vock
collection DOAJ
description AIMS: Aminoglycoside resistance is frequently detected in extended-spectrum-beta-lactamase (ESBL)-producing Enterobacterales (ESBL-PE), questioning the appropriateness of aminoglycosides as empiric therapy in patients with suspected ESBL-PE infections. Therefore, we aimed to evaluate the frequency of aminoglycoside resistance in patients harbouring ESBL-PE and identify patient-related risk factors associated with aminoglycoside resistance to facilitate early detection of at-risk patients. METHODS: This retrospective single-centre cohort study included hospitalised patients aged ≥18 years with an ESBL-PE-positive sample between January 2016 and December 2018. Aminoglycoside resistance was defined according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints for Enterobacterales for the current year of testing. RESULTS: Five hundred forty-four patients met the eligibility criteria, of which 240 (44.1%) harboured aminoglycoside-resistant ESBL strains. Identification of ESBL-Klebsiella pneumoniae was significantly associated with aminoglycoside resistance (odds ratio [OR] = 2.64, 95% confidence interval [CI] = 1.65–4.21, p <0.001) and an international travel history within the past 12 months was marginally associated with aminoglycoside resistance (OR = 1.51, 95% CI = 0.95–2.42, p = 0.084). CONCLUSIONS: In a low ESBL endemicity setting, aminoglycoside resistance in patients harbouring ESBL-PE is common, especially ESBL-K. pneumoniae, and needs to be considered in clinicians’ decision-making regarding empiric therapy regimens.
format Article
id doaj-art-a34fbbfd98b7481fb2252e19f5259525
institution OA Journals
issn 1424-3997
language English
publishDate 2024-10-01
publisher SMW supporting association (Trägerverein Swiss Medical Weekly SMW)
record_format Article
series Swiss Medical Weekly
spelling doaj-art-a34fbbfd98b7481fb2252e19f52595252025-08-20T02:18:10ZengSMW supporting association (Trägerverein Swiss Medical Weekly SMW)Swiss Medical Weekly1424-39972024-10-011541010.57187/s.3904Quantifying aminoglycoside resistance in extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales clinical isolates: a retrospective cohort studyIsabelle VockLisandra Aguilar-BultetNina KhannaAdrian EgliElisabeth Wehrle-WielandPranita D. TammaSarah Tschudin Sutter0University Hospital Basel, Switzerland AIMS: Aminoglycoside resistance is frequently detected in extended-spectrum-beta-lactamase (ESBL)-producing Enterobacterales (ESBL-PE), questioning the appropriateness of aminoglycosides as empiric therapy in patients with suspected ESBL-PE infections. Therefore, we aimed to evaluate the frequency of aminoglycoside resistance in patients harbouring ESBL-PE and identify patient-related risk factors associated with aminoglycoside resistance to facilitate early detection of at-risk patients. METHODS: This retrospective single-centre cohort study included hospitalised patients aged ≥18 years with an ESBL-PE-positive sample between January 2016 and December 2018. Aminoglycoside resistance was defined according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints for Enterobacterales for the current year of testing. RESULTS: Five hundred forty-four patients met the eligibility criteria, of which 240 (44.1%) harboured aminoglycoside-resistant ESBL strains. Identification of ESBL-Klebsiella pneumoniae was significantly associated with aminoglycoside resistance (odds ratio [OR] = 2.64, 95% confidence interval [CI] = 1.65–4.21, p <0.001) and an international travel history within the past 12 months was marginally associated with aminoglycoside resistance (OR = 1.51, 95% CI = 0.95–2.42, p = 0.084). CONCLUSIONS: In a low ESBL endemicity setting, aminoglycoside resistance in patients harbouring ESBL-PE is common, especially ESBL-K. pneumoniae, and needs to be considered in clinicians’ decision-making regarding empiric therapy regimens. https://smw.ch/index.php/smw/article/view/3904
spellingShingle Isabelle Vock
Lisandra Aguilar-Bultet
Nina Khanna
Adrian Egli
Elisabeth Wehrle-Wieland
Pranita D. Tamma
Sarah Tschudin Sutter
Quantifying aminoglycoside resistance in extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales clinical isolates: a retrospective cohort study
Swiss Medical Weekly
title Quantifying aminoglycoside resistance in extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales clinical isolates: a retrospective cohort study
title_full Quantifying aminoglycoside resistance in extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales clinical isolates: a retrospective cohort study
title_fullStr Quantifying aminoglycoside resistance in extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales clinical isolates: a retrospective cohort study
title_full_unstemmed Quantifying aminoglycoside resistance in extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales clinical isolates: a retrospective cohort study
title_short Quantifying aminoglycoside resistance in extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales clinical isolates: a retrospective cohort study
title_sort quantifying aminoglycoside resistance in extended spectrum beta lactamase esbl producing enterobacterales clinical isolates a retrospective cohort study
url https://smw.ch/index.php/smw/article/view/3904
work_keys_str_mv AT isabellevock quantifyingaminoglycosideresistanceinextendedspectrumbetalactamaseesblproducingenterobacteralesclinicalisolatesaretrospectivecohortstudy
AT lisandraaguilarbultet quantifyingaminoglycosideresistanceinextendedspectrumbetalactamaseesblproducingenterobacteralesclinicalisolatesaretrospectivecohortstudy
AT ninakhanna quantifyingaminoglycosideresistanceinextendedspectrumbetalactamaseesblproducingenterobacteralesclinicalisolatesaretrospectivecohortstudy
AT adrianegli quantifyingaminoglycosideresistanceinextendedspectrumbetalactamaseesblproducingenterobacteralesclinicalisolatesaretrospectivecohortstudy
AT elisabethwehrlewieland quantifyingaminoglycosideresistanceinextendedspectrumbetalactamaseesblproducingenterobacteralesclinicalisolatesaretrospectivecohortstudy
AT pranitadtamma quantifyingaminoglycosideresistanceinextendedspectrumbetalactamaseesblproducingenterobacteralesclinicalisolatesaretrospectivecohortstudy
AT sarahtschudinsutter quantifyingaminoglycosideresistanceinextendedspectrumbetalactamaseesblproducingenterobacteralesclinicalisolatesaretrospectivecohortstudy